OncoCyte (OCX) Short Interest Ratio & Short Volume → Everybody laughed when he recommended Netflix (From Stansberry Research) (Ad) Free OCX Stock Alerts $2.76 -0.17 (-5.80%) (As of 04:00 PM ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media OncoCyte Short Interest DataCurrent Short Interest374,200 sharesPrevious Short Interest233,100 sharesChange Vs. Previous Month+60.53%Dollar Volume Sold Short$931,758.00Short Interest Ratio6.6 Days to CoverLast Record DateApril 30, 2024Outstanding Shares8,270,000 sharesFloat Size10,290,000 sharesShort Percent of Float3.64%Today's Trading Volume19,615 sharesAverage Trading Volume44,326 sharesToday's Volume Vs. Average44% Short Selling OncoCyte ? Sign up to receive the latest short interest report for OncoCyte and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartOCX Short Interest Over TimeOCX Days to Cover Over TimeOCX Percentage of Float Shorted Over Time Ad Huge Alerts**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! Learn more about why Zack’s has increased its price target on this company to a whopping $23.25!Click for Zack's full report OncoCyte Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/2024374,200 shares $931,758.00 +60.5%3.6%6.6 $2.49 4/15/2024233,100 shares $589,743.00 +30.2%3.1%4.2 $2.53 3/31/2024179,100 shares $524,763.00 +0.5%2.4%21.3 $2.93 3/15/2024178,300 shares $531,334.00 +0.4%2.4%13.5 $2.98 2/29/2024177,600 shares $516,816.00 -2.8%2.3%13.1 $2.91 2/15/2024182,800 shares $524,636.00 -1.5%2.4%14.3 $2.87 Get the Latest News and Ratings for OCX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for OncoCyte and its competitors with MarketBeat's FREE daily newsletter. 1/31/2024185,600 shares $575,360.00 -5.7%2.4%10.3 $3.10 1/15/2024196,800 shares $661,248.00 +8.3%2.6%10.6 $3.36 12/31/2023181,800 shares $454,500.00 -4.4%2.4%9.2 $2.50 12/15/2023190,100 shares $589,310.00 -10.4%2.5%11.7 $3.10 11/30/2023212,200 shares $806,360.00 +4.7%2.8%14.4 $3.80 11/15/2023202,600 shares $802,296.00 -1.1%2.7%13.2 $3.96 10/31/2023204,800 shares $464,896.00 +8.4%2.7%15.8 $2.27 10/15/2023188,900 shares $612,980.50 +0.9%2.5%9.9 $3.25 9/30/2023187,200 shares $584,064.00 +0.7%2.5%10 $3.12 9/15/2023185,900 shares $593,021.00 +8.3%2.5%9.4 $3.19 8/31/2023171,600 shares $616,044.00 +3.5%2.3%8.2 $3.59 8/15/2023165,800 shares $553,772.00 +157.9%2.2%7.9 $3.34 7/31/202364,300 shares $268,131.00 +43.2%0.9%3.2 $4.17 7/15/202344,900 shares $195,135.40 -95.6%N/A3.5 $4.35 6/30/20231,020,000 shares $234,600.00 -4.7%N/A3.4 $0.23 6/15/20231,070,000 shares $230,050.00 -24.7%N/A3.2 $0.22 5/31/20231,420,000 shares $303,454.00 +22.4%N/A2.7 $0.21 5/15/20231,160,000 shares $308,560.00 -2.5%N/A2.3 $0.27 4/30/20231,190,000 shares $326,060.00 -14.4%N/A2.4 $0.27 4/15/20231,390,000 shares $443,688.00 +5.3%N/A2.8 $0.32 3/31/20231,320,000 shares $467,808.00 +6.5%N/A2.8 $0.35 3/15/20231,240,000 shares $248,000.00 +24.0%N/A2.7 $0.20 2/28/20231,000,000 shares $363,900.00 -4.8%N/A3.6 $0.36 2/15/20231,050,000 shares $471,975.00 -13.2%N/A3.6 $0.45 1/31/20231,210,000 shares $465,971.00 -14.2%N/A3.1 $0.39 1/15/20231,410,000 shares $688,080.00 -16.6%N/A3.4 $0.49 12/30/20221,690,000 shares $542,321.00 -14.7%N/A4.1 $0.32 12/15/20221,980,000 shares $792,000.00 -4.4%N/A5.1 $0.40 11/30/20222,070,000 shares $973,107.00 -12.7%N/A6.5 $0.47 11/15/20222,370,000 shares $967,908.00 -6.3%N/A6.1 $0.41 10/31/20222,530,000 shares $1.73 million -1.9%N/A7.9 $0.68 10/15/20222,580,000 shares $2.00 million -1.5%N/A9.1 $0.78 9/30/20222,620,000 shares $1.91 million +5.7%N/A8.8 $0.73 9/15/20222,480,000 shares $2.23 million -8.2%N/A5.6 $0.90Read this before you buy AI stocks (Ad)BREAKING: New "Formula" Could Lead to Huge AI Payouts When you click here and see what Elon Musk's new invention does… Investors — including multiple billionaires — are now tapping into a unique AI secret to pocket huge, consistent payouts. Starting today, you could siphon a new stream of income from this $3 billion pool of cash. 8/31/20222,700,000 shares $2.13 million No ChangeN/A5.5 $0.79 7/30/20213,040,000 shares $0.00 -3.8%3.6%6.9 $0.00 7/15/20213,160,000 shares $0.00 +2.6%3.6%6.9 $0.00 6/30/20213,080,000 shares $0.00 -4.6%3.6%6.2 $0.00 6/15/20213,230,000 shares $0.00 +14.1%3.8%6.4 $0.00 5/28/20212,830,000 shares $0.00 +2.9%3.3%4.5 $0.00 5/14/20212,750,000 shares $0.00 -0.4%N/A3.6 $0.00 4/30/20212,760,000 shares $0.00 +0.7%N/A2.9 $0.00 4/15/20212,740,000 shares $12.38 million +19.7%N/A2.2 $4.52 3/31/20212,290,000 shares $11.45 million +9.1%N/A1.6 $5.00 3/15/20212,100,000 shares $10.94 million +6.1%N/A1.4 $5.21 2/26/20211,980,000 shares $9.41 million +4.2%6.6%0.8 $4.75 2/12/20211,900,000 shares $7.07 million -4.5%N/A0.8 $3.72 1/29/20211,990,000 shares $11.66 million -21.3%N/A0.9 $5.86 1/15/20212,530,000 shares $14.07 million +1.2%N/A1.3 $5.56 12/31/20202,500,000 shares $6.08 million +12.6%N/A1.1 $2.43 12/15/20202,220,000 shares $4.71 million -14.3%N/A1.1 $2.12 11/30/20202,590,000 shares $4.64 million +7.5%N/A2.7 $1.79 11/15/20202,410,000 shares $4.19 million -0.8%N/A2.3 $1.74 10/30/20202,430,000 shares $3.86 million +4.3%N/A2.3 $1.59 10/15/20202,330,000 shares $4.08 million -17.1%N/A1.9 $1.75 9/30/20202,810,000 shares $3.91 million +24.9%N/A3.3 $1.39 9/15/20202,250,000 shares $3.26 million +23.6%N/A2 $1.45 8/31/20201,820,000 shares $2.28 million +8.3%N/A1.6 $1.25 8/14/20201,680,000 shares $2.94 million -5.6%N/A1.7 $1.75 7/31/20201,780,000 shares $2.40 million +2.3%N/A1.8 $1.35 7/15/20201,740,000 shares $2.21 million -7.0%N/A2.2 $1.27 6/30/20201,870,000 shares $6.04 million +52.0%N/A2.7 $3.23 6/15/20201,230,000 shares $2.93 million +4.2%N/A3.4 $2.38 5/29/20201,180,000 shares $3.10 million +0.9%N/A4.3 $2.63 5/15/20201,170,000 shares $3.40 million +1.7%N/A4.6 $2.91 4/30/20201,150,000 shares $3.11 million -1.7%N/A5.2 $2.70 4/15/20201,170,000 shares $2.71 million -1.7%2.4%6.8 $2.32 3/31/20201,190,000 shares $2.84 million -9.4%2.5%4.6 $2.39 3/13/20201,313,100 shares $3.20 million +1.8%3.2%4.5 $2.44 2/28/20201,290,000 shares $2.49 million +7.5%2.7%4.4 $1.93 2/14/20201,200,000 shares $2.75 million +5.3%2.5%3.9 $2.29 1/31/20201,140,000 shares $2.87 million -1.7%2.4%3.8 $2.52 1/15/20201,160,000 shares $2.90 million -7.2%2.5%4 $2.50 12/31/20191,250,000 shares $3.49 million No Change2.7%4.8 $2.79 8/15/20191,007,700 shares $1.90 million -18.8%3.3%2.8 $1.89 OCX Short Interest - Frequently Asked Questions What is OncoCyte's current short interest? Short interest is the volume of OncoCyte shares that have been sold short but have not yet been closed out or covered. As of April 30th, traders have sold 374,200 shares of OCX short. 3.64% of OncoCyte's shares are currently sold short. Learn More on OncoCyte's current short interest. What is a good short interest ratio for OncoCyte? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. OCX shares currently have a short interest ratio of 7.0. Learn More on OncoCyte's short interest ratio. What is a good short interest percentage for OncoCyte? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 3.64% of OncoCyte's floating shares are currently sold short. Is OncoCyte's short interest increasing or decreasing? OncoCyte saw a increase in short interest in April. As of April 30th, there was short interest totaling 374,200 shares, an increase of 60.5% from the previous total of 233,100 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is OncoCyte's float size? OncoCyte currently has issued a total of 8,270,000 shares. Some of OncoCyte's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. OncoCyte currently has a public float of 10,290,000 shares. How does OncoCyte's short interest compare to its competitors? 3.64% of OncoCyte's shares are currently sold short. Here is how the short interest of companies compare to OncoCyte: DURECT Co. (3.24%), Cardio Diagnostics Holdings, Inc. (1.92%), Aspira Women's Health Inc. (2.50%), Trinity Biotech plc (0.02%), Achilles Therapeutics plc (0.06%), Biomerica, Inc. (0.64%), ImmuCell Co. (0.09%), ARCA biopharma, Inc. (30.24%), InflaRx (0.22%), Alpha Teknova, Inc. (0.50%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short OncoCyte stock? Short selling OCX is an investing strategy that aims to generate trading profit from OncoCyte as its price is falling. OCX shares are trading down $0.17 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against OncoCyte? A short squeeze for OncoCyte occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of OCX, which in turn drives the price of the stock up even further. How often is OncoCyte's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including OCX, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: DRRX Short Interest Data CDIO Short Interest Data AWH Short Interest Data TRIB Short Interest Data ACHL Short Interest Data BMRA Short Interest Data ICCC Short Interest Data ABIO Short Interest Data IFRX Short Interest Data TKNO Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:OCX) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDoes this make you sick?Allegiance GoldThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street Star**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! Huge AlertsWarren Buffett's "mystery stock"Stansberry ResearchThis Could be Your “Big Money” AI MomentInvestorPlace